The purpose of this study is to determine the safety of a new formulation of the omega-3
fatty acids Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) and to assess whether
it decreases inflammation and inflammatory pain in children and young adults with Sickle Cell
Disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Robin E. Miller
Collaborators:
National Institute of General Medical Sciences (NIGMS) Solutex GC, S.L. Thomas Jefferson University